Population pharmacokinetics and individualized lobaplatin regimen for the treatment of Chinese small cell lung cancer in the elderly

BACKGROUND: Lobaplatin (LBP) is a third-generation platinum compound. MATERIAL AND METHODS: This prospective study was performed in 7 institutions in 2014–2016. Elderly small cell lung cancer (SCLC) patients (≥65 years old) were divided into 2 groups to receive LBP regimens according to endogenous c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying, Wu, Lin, Liu, Xiaoqing, Zhao, Yanqiu, Liu, Chunling, Chen, Qun, Sun, Tao, Zheng, Qingshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370119/
https://www.ncbi.nlm.nih.gov/pubmed/30653145
http://dx.doi.org/10.1097/MD.0000000000014136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370119/
https://www.ncbi.nlm.nih.gov/pubmed/30653145
http://dx.doi.org/10.1097/MD.0000000000014136

Ejemplares similares